# Clinical trials recruiting in Kentucky: 1,009 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 1,009 trials recruiting or not yet recruiting with a site in Kentucky, as read on November 19, 2026.

## The full list

Clinical trials recruiting in Kentucky: 1,009 rows for $50.45, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 14 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/state/kentucky

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 1,009
- Recruiting or not yet: 1,009
- Read on: November 19, 2026

## Trials

The 25 newest of 1,009, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07946627 | Everolimus Post-Bland Hepatic Artery Embolization in Patients With Neuroendocrine Tumors (NETs) With Liver Metastasis | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Neuroendocrine Tumors, Liver Metastases | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07946627) |
| November 12, 2026 | NCT07930936 | Immunotherapy and Irreversible Electroporation (IRE) in the Treatment of Locally Advanced Pancreatic Adenocarcinoma | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Locally Advanced Pancreatic Adenocarcinoma | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07930936) |
| November 6, 2026 | NCT07923591 | Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic... | United Therapeutics | Phase 2 | Not yet recruiting | Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923591) |
| November 6, 2026 | NCT07923526 | An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic... | United Therapeutics | Phase 2/3 | Not yet recruiting | Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923526) |
| November 6, 2026 | NCT07923045 | A Phase 1/2 Clinical Trial to Evaluate the Safety and Efficacy of MR-146 in Subjects With Stage I and Stage II Neurotrophic Keratopathy | Viatris Inc. | Phase 1/2 | Recruiting | Neurotrophic Keratopathy | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923045) |
| November 5, 2026 | NCT07919405 | A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Hypertension, Obesity | 1,408 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919405) |
| November 2, 2026 | NCT07908316 | Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After... | Amgen | Phase 1 | Recruiting | Obesity, Overweight | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908316) |
| October 22, 2026 | NCT07888179 | Scaling up the DSMES Learning Collaborative | Sponsor not shown (see the record) | Not applicable | Not yet recruiting | Type Two Diabetes Mellitus | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07888179) |
| October 20, 2026 | NCT07884175 | A Study of Updated mRNA Seasonal Influenza Vaccines | ModernaTX, Inc. | Phase 4 | Recruiting | Seasonal Influenza | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07884175) |
| October 20, 2026 | NCT07881952 | Safety and Systemic Exposure of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris) (COVE-5) | Verrica Pharmaceuticals Inc. | Phase 2 | Not yet recruiting | Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881952) |
| October 9, 2026 | NCT07868835 | Oral VK2735 for Weight Management Phase 3 (SUNRISE 1) | Viking Therapeutics, Inc. | Phase 3 | Recruiting | Weight Loss | 560 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07868835) |
| October 7, 2026 | NCT07863635 | A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations | ModernaTX, Inc. | Phase 4 | Recruiting | SARS-CoV-2 | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07863635) |
| October 6, 2026 | NCT07861100 | A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Cardiovascular Risk, Obesity | 8,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07861100) |
| September 30, 2026 | NCT07849699 | Implementing Stepped Financial and Legal Navigation to Mitigate Financial Toxicity in Adolescent and Young Adult Cancer Patients Oncology... | University of Louisville | Not applicable | Not yet recruiting | Financial Toxicity, Cancer, Adolescent, Young Adult Cancer Survivors | 294 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07849699) |
| September 29, 2026 | NCT07845500 | A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With... | Pfizer | Phase 3 | Recruiting | Obesity, Overweight and/or Obesity, Overweight, Treatment Of Obesity | 660 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07845500) |
| September 25, 2026 | NCT07842601 | Helping Kentuckians Overcome Depression and Opioid Addiction With Brain Stimulation | University of Kentucky | Not applicable | Recruiting | Opioid Use Disorder, Major Depressive Disorder (MDD) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07842601) |
| September 18, 2026 | NCT07828860 | Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa | Corvus Pharmaceuticals, Inc. | Phase 1 | Recruiting | Hidradenitis Suppurativa (HS) | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07828860) |
| September 15, 2026 | NCT07819435 | Phase 2/3 Efficacy and Safety of PP405 in Adult Males | Pelage Pharmaceuticals, Inc. | Phase 2/3 | Recruiting | Androgenetic Alopecia | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07819435) |
| September 14, 2026 | NCT07817875 | Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12... | Eli Lilly and Company | Phase 3 | Recruiting | Obesity | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07817875) |
| September 11, 2026 | NCT07816185 | A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier) | Pulmovant, Inc. | Phase 3 | Recruiting | Pulmonary Hypertension, Interstitial Lung Disease, Vascular Diseases, Cardiovascular Diseases, Fibrosis | 376 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07816185) |
| September 10, 2026 | NCT07812285 | The Impact of Osteopathic Manipulative Treatment on Pelvic Floor Dysfunction, Activity, and Gait in Female Runners | Sponsor not shown (see the record) | Not applicable | Recruiting | Pelvic Floor Disfunction | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07812285) |
| September 9, 2026 | NCT07810790 | Upper Extremity Vascularized Composite Allotransplantation: A Study Evaluating Safety, Functional Outcomes, and Patient-Reported... | Yale University | Not applicable | Not yet recruiting | Functional Recovery, Upper Extremity Vascularized Composite Allotransplantation | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07810790) |
| September 9, 2026 | NCT07810764 | Facial Vascularized Composite Allotransplantation: A Study Evaluating Safety, Functional Outcomes, and Patient-Reported Psychosocial... | Yale University | Not applicable | Not yet recruiting | Facial Vascularized Composite Allotransplantation, Functional Recovery | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07810764) |
| September 8, 2026 | NCT07806799 | Radon on the RADAR (Residents Acting to Detect and Alleviate Radon) 2.0 | Sponsor not shown (see the record) | Not applicable | Recruiting | Radon Exposure | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07806799) |
| September 4, 2026 | NCT07804121 | Project SHIELD 2.0: Police Education to Support Public Health in Kentucky | Johns Hopkins Bloomberg School of Public Health | Not applicable | Recruiting | HIV, Substance Use Disorder (SUD) | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07804121) |

## Sites with the most of these trials

Sites as the records name them, organizations only.

| Site | City | Trials |
| --- | --- | --- |
| University of Kentucky | Lexington | 125 |
| University of Kentucky/Markey Cancer Center | Lexington | 92 |
| University of Louisville | Louisville | 60 |
| UofL Health Medical Center Northeast | Louisville | 50 |
| Saint Joseph Radiation Oncology Resource Center | Lexington | 39 |
| Norton Cancer Institute | Louisville | 38 |
| The James Graham Brown Cancer Center at University of Louisville | Louisville | 37 |
| Commonwealth Cancer Center-Corbin | Corbin | 35 |
| Baptist Health Lexington | Lexington | 34 |
| CommonSpirit Saint Joseph Medical Center - East Lexington | Lexington | 32 |
| Norton Children's Hospital | Louisville | 29 |
| CommonSpirit Saint Joseph Hospital - Bardstown | Bardstown | 25 |
| CommonSpirit Saint Joseph Hospital London | London | 24 |
| Baptist Health Louisville | Louisville | 23 |
| Jewish Hospital | Louisville | 20 |
| CommonSpirit Saint Joseph Hospital - Lexington | Lexington | 20 |
| Saints Mary and Elizabeth Hospital | Louisville | 19 |
| Jewish Hospital Medical Center South | Shepherdsville | 19 |
| Saint Joseph Hospital East | Lexington | 16 |
| CommonSpirit Saint Joseph Hospital Mount Sterling | Mount Sterling | 16 |
| University of Louisville Hospital | Louisville | 16 |
| University of Kentucky Medical Center | Lexington | 15 |
| Flaget Memorial Hospital | Bardstown | 14 |
| University of Kentucky Markey Cancer Center | Lexington | 14 |
| University of Kentucky Chandler Medical Center | Lexington | 14 |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 6 |
| Phase 1 | 57 |
| Phase 1/2 | 59 |
| Phase 2 | 178 |
| Phase 2/3 | 34 |
| Phase 3 | 330 |
| Phase 4 | 33 |
| Not applicable | 181 |
| Observational | 131 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 55 |
| Neoplasms | 34 |
| Obesity | 34 |
| Lung Neoplasms | 31 |
| Breast Neoplasms | 27 |
| Overweight | 24 |
| Melanoma | 22 |
| Ovarian Neoplasms | 22 |
| Colorectal Neoplasms | 21 |
| Heart Failure | 21 |
| Squamous Cell Carcinoma of Head and Neck | 20 |
| Prostatic Neoplasms | 20 |
| Neoplasm Metastasis | 18 |
| Small Cell Lung Carcinoma | 17 |
| Multiple Myeloma | 17 |
| Cardiovascular Diseases | 15 |
| Diabetes Mellitus, Type 2 | 14 |
| Leukemia, Myeloid, Acute | 14 |
| Atrial Fibrillation | 14 |
| Lymphoma, Large B-Cell, Diffuse | 14 |
| Endometrial Neoplasms | 13 |
| Pancreatic Neoplasms | 13 |
| Carcinoma, Renal Cell | 12 |
| Colitis, Ulcerative | 12 |
| Hematologic Neoplasms | 12 |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| National Cancer Institute (NCI) | 50 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 41 |
| University of Louisville | 36 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 28 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 27 |
| SWOG Cancer Research Network | 22 |
| Children's Oncology Group | 19 |
| Alliance for Clinical Trials in Oncology | 18 |
| NRG Oncology | 16 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 16 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 12 |
| [Janssen Research & Development, LLC](https://specstream.ai/data/clinical-trials/company/janssen-research-and-development-llc) | 12 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 11 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 11 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 10 |
| [Amgen](https://specstream.ai/data/clinical-trials/company/amgen) | 9 |
| [Novo Nordisk A/S](https://specstream.ai/data/clinical-trials/company/novo-nordisk-a-s) | 9 |
| [Sanofi](https://specstream.ai/data/clinical-trials/company/sanofi) | 9 |
| ECOG-ACRIN Cancer Research Group | 9 |
| [Boehringer Ingelheim](https://specstream.ai/data/clinical-trials/company/boehringer-ingelheim) | 7 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 7 |
| [BioNTech SE](https://specstream.ai/data/clinical-trials/company/biontech-se) | 7 |
| [Takeda](https://specstream.ai/data/clinical-trials/company/takeda) | 7 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 7 |
| Duke University | 6 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in Kentucky

- [Comfort food restaurants in Kentucky, United States](https://specstream.ai/data/businesses/comfort-food-restaurants/kentucky-united-states)
- [Vocational and technical schools in Kentucky, United States](https://specstream.ai/data/businesses/vocational-and-technical-schools/kentucky-united-states)
- [Physical therapy clinics in Kentucky, United States](https://specstream.ai/data/businesses/physical-therapy-clinics/kentucky-united-states)
- [Hospices in Kentucky, United States](https://specstream.ai/data/businesses/hospices/kentucky-united-states)
- [Cleaning companies in Kentucky, United States](https://specstream.ai/data/businesses/cleaning-companies/kentucky-united-states)
- [Urgent care clinics in Kentucky, United States](https://specstream.ai/data/businesses/urgent-care-clinics/kentucky-united-states)
